RxDoctor Payments Data

David Hojnacki, MD

Neurology · Buffalo, NYNPI 1205848306

Payments from drug & device makers

$525,802in general payments, 2019–2025

Across 511 payments — averaging $1028.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$242K
  • EMD Serono, Inc.$104K
  • Bristol Myers Squibb$82K
  • Novartis$38K
  • Genentech USA, Inc.$26K
  • AstraZeneca$20K
  • plus $14K from 11 others

What the payments were for

  • Consulting fees$89,20219%
  • Speaking & faculty fees$337,42770%
  • Travel & lodging$41,6359%
  • Food & beverage$11,1672%
  • Education$1420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen179$241,798
EMD Serono, Inc.67$104,092
Bristol Myers Squibb72$82,096
Novartis37$38,101
Genentech USA, Inc.68$25,761
AstraZeneca(2 entities)32$19,567
Amgen(2 entities)27$9,527
E.r. Squibb & Sons, L.L.C.4$4,081
TG Therapeutics, Inc.3$341
Pfizer6$122
Sanofi4$81
Johnson & Johnson(2 entities)4$69
CSL Behring3$66
Neurelis, Inc.2$38
UCB, Inc.1$25
Argenx US, Inc.1$18
Mallinckrodt Hospital Products Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$525,802 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$725,233
Medicare patients
217
Services billed
15,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a154$1,254,861
CopaxoneGlatiramer Acetate90$515,333
Plegridy PenPeginterferon Beta-1a30$307,617
TecfideraDimethyl Fumarate34$303,694
Avonex (4 Pack)Interferon Beta-1a33$265,430
Kesimpta PenOfatumumab23$247,926
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5052$167,115
GlatopaGlatiramer Acetate37$135,818
Glatiramer Acetate45$127,014
VumerityDiroximel Fumarate12$104,680
TysabriNatalizumab11$80,370
Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-5013$65,861
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5015$61,038
Teriflunomide33$44,577
Dalfampridine ErDalfampridine116$42,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Avonex (4 Pack), Vumerity, Tysabri$241,798$754,17490 claims
CSL BehringPrivigen$66$41,84912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →